Hengrui’s Docetaxel Use Ruled Not Infringing On Sanofi-Aventis’ Patent
This article was originally published in PharmAsia News
Executive Summary
Hengrui China's Patent Re-examination Board of the State Intellectual Property Office (SIPO) has ruled that the patent right of Aventis Pharma S.A. and Sanofi-Aventis for Docetaxel is invalid. If dissatisfied with the verdict, the plaintiffs can appeal to the Beijing Number One Intermediate People's Court within three months. Last September, Aventis Pharma and Sanofi-Aventis sued Jiangsu Hengrui in Beijing Municipal Higher People's Court for Docetaxel patent infringement, asking for patent fees of 45 million yuan ($6.4 million), financial loss compensation of 55 million yuan ($7.87 million), miscellaneous expenses of 200,000 yuan ($28,000) and full cost of the litigation. (Click here for more - Chinese language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.